Lilly links COVID-19 antibody to a reduce hospitalization rate Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients lately diagnosed with mild to moderate cases of COVID-19. Nevertheless, two of the three doses, including the highest studied in the phase 2 trial, flunk...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.